New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
New findings from MS PATHS show that treatment with TYSABRI® (natalizumab) can lead to meaningful improvements in…